ARDC vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe operational and balance sheet deterioration. Despite a current price of $13.50 and a seemingly low P/E of 10.80, the lack of profitability metrics (0% margins across the board), absence of key financial ratios, and a dangerously high 110.8% payout ratio undermine sustainability. The stock trades well above its growth-approximated intrinsic value of $8.75, with no Altman Z-Score to counterbalance bankruptcy risk. Technical trend is deeply bearish (0/100), and insider sentiment is weak, further validating caution.
JPM shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Key strengths include strong valuation and growth metrics. Price trades at a 109.8% premium to fair value estimate ($140.21), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
ARDC vs JPM: Head-to-Head Comparison
This page compares Ares Dynamic Credit Allocation Fund, Inc. (ARDC) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.